

May 6, 2021

Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Dainippon Pharma Announces Investment in Special Purpose Acquisition Company Combining with Roivant Sciences

Sumitomo Dainippon Pharma Co., Ltd. (Head Office: Osaka, Japan; Representative Director, President and CEO: Hiroshi Nomura; Securities Code: 4506, First Section of TSE) announced today that it has entered into a subscription agreement (hereinafter, "the Agreement") with Montes Archimedes Acquisition Corp. (Headquarters: Menlo Park, California, U.S.; Founder, Chairman and CEO: Jim Montazee; Nasdaq; hereinafter, "MAAC"), a special purpose acquisition company that has entered into a business combination agreement (hereinafter, the "BCA") to combine with Roivant Sciences Ltd. (Headquarters: London, U.K., Basel, Switzerland; CEO: Matthew Gline; hereinafter, "Roivant")

For more information on the BCA, please see below for Roivant press release dated May 3, 2021. <https://roivant.com/roivant-sciences-and-montes-archimedes-acquisition-corp-maac-to-combine-and-create-publicly-traded-leader-in-biopharma-and-health-technology.html>

Following the completion of the transactions contemplated by the BCA (hereinafter, the "Transaction"), Roivant is expected to be listed on Nasdaq under the ticker symbol "ROIV." The Transaction remains subject to the approval of MAAC's shareholders and other customary closing conditions.

In conjunction with entry into the BCA, MAAC and Roivant have entered into private investment in public equity subscription agreements with several investors, including Sumitomo Dainippon Pharma, with committed funding of \$200 million total (collectively, hereinafter, the "PIPE Investments"). The closing of the PIPE Investments is subject to, and will take place concurrently with, the closing of the Transaction. Based on the Agreement, Sumitomo Dainippon Pharma will acquire shares of MAAC which will be converted into common shares of Roivant upon the acquisition at the closing of the Transaction.

Reference Information

About Roivant

Roivant was founded in 2014 and is a private company. Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. Roivant does this by building Vants – nimble, entrepreneurial biotech and healthcare companies with a unique approach to sourcing talent, aligning incentives, and deploying technology to drive greater efficiency in R&D and commercialization. In 2019, Sumitomo Dainippon Pharma acquired 11% of Roivant's shares (\$1 billion) through a strategic alliance agreement with the company.

About Montes Archimedes Acquisition Corp. (MAAC)

MAAC is a special purpose acquisition company listed on Nasdaq with a focus on the health care industry. MAAC was formed for the purpose of effecting a merger, capital stock exchange, reorganization or similar business combination with one or more businesses and was publicly listed on Nasdaq in October 2020. For more information, please visit <https://montesarchimedesacquisitioncorp.com/>.

Contact:

Corporate Communications

Sumitomo Dainippon Pharma Co., Ltd.

TEL: +81-6-6203-1407 (Osaka); +81-3-5159-3300 (Tokyo)